{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/management/management/","result":{"pageContext":{"chapter":{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 59efa41b-b45c-43b5-8985-4c2356a69323 --><h2>Scenario: Management</h2><!-- end field 59efa41b-b45c-43b5-8985-4c2356a69323 -->","summary":"Covers information on treatments for prostate cancer, and advice on information resources and support groups for men with prostate cancer.","htmlStringContent":"<!-- begin item d06fd6fd-a83c-4140-890e-74d5d6d82af6 --><!-- begin field 2cdbc811-b0f3-47fb-902c-acd900adef06 --><p>From age 30 years onwards (Male).</p><!-- end field 2cdbc811-b0f3-47fb-902c-acd900adef06 --><!-- end item d06fd6fd-a83c-4140-890e-74d5d6d82af6 -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d1f95b0f-55fd-5a65-bce6-63c7936763e8","slug":"overview","fullItemName":"Overview","depth":3,"htmlHeader":"<!-- begin field f22a3e4b-ace0-41f2-862f-714c6bef6368 --><h3>How is prostate cancer managed? </h3><!-- end field f22a3e4b-ace0-41f2-862f-714c6bef6368 -->","summary":null,"htmlStringContent":"<!-- begin item b8a515df-3898-418e-aa82-616ff989d80d --><!-- begin field 4c52be54-b67b-4609-a355-dd3da03abafe --><ul><li>Treatment for prostate cancer will be initiated and managed in secondary care.<ul><li>Follow up and monitoring, as well as early recognition and initial management of the <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/complications-adverse-effects/\">complications</a> of the condition and adverse effects of its treatment can be carried out in primary care under shared care arrangements. </li></ul></li><li>Management options in secondary care depend on the man's prognostic risk, which is determined after taking into account the: <ul><li>Clinical staging.</li><li>Results of the <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/diagnosis/psa-testing/\">prostate-specific antigen (PSA) test</a>.</li><li>Gleason score.</li></ul></li><li>Other considerations include age and comorbidities, as well as the man's preferences. </li><li><strong>Treatments options for prostate cancer include: </strong><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#watchful-waiting\">Watchful waiting</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#active-surveillance\">active surveillance</a>.</li><li>Radical treatments, such as <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#radical-prostatectomy\">radical prostatectomy</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#external-beam-radiotherapy\">external beam radiotherapy</a>, or <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#brachytherapy\">brachytherapy</a>.<ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#high-intensity-focused-ultrasound\">High intensity focused ultrasound</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#cryotherapy\">cryotherapy</a> should not be used except in controlled clinical trials comparing their use with established interventions.</li></ul></li><li>Adjunctive and palliative treatments, such as <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#hormonal-treatments\">hormone therapy</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#strontium-89\">strontium-89 therapy</a>, radium-223 therapy, <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#chemotherapy\">chemotherapy</a>, or <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#bisphosphonates\">bisphosphonates</a>.</li></ul></li></ul><!-- end field 4c52be54-b67b-4609-a355-dd3da03abafe --><!-- end item b8a515df-3898-418e-aa82-616ff989d80d -->","subChapters":[{"id":"b8cb632a-c642-57e7-8d51-df82b359b3d8","slug":"staging","fullItemName":"Staging","depth":4,"htmlHeader":"<!-- begin field 732c672a-808e-4444-b240-a7bb00e9b4d7 --><h4>What is the staging for prostate cancer?</h4><!-- end field 732c672a-808e-4444-b240-a7bb00e9b4d7 -->","summary":null,"htmlStringContent":"<!-- begin item 498dfa03-c2bb-4bf5-9168-a7bb00e9ac31 --><!-- begin field c686103d-4875-4839-818e-a7bb00e9b4d7 --><p><strong>Table 2.</strong> Tumour Node Metastasis (TNM) classification of prostate cancer</p><table data-table-id=\"b1eef5b9-f23c-4c72-af47-acce014c909f\"><tbody><tr><td colspan=\"2\"><strong>T – Primary tumour</strong></td></tr><tr><td>TX</td><td>Primary tumour cannot be assessed</td></tr><tr><td>T0</td><td>No evidence of primary tumour</td></tr><tr><td rowspan=\"1\"><strong>T1</strong></td><td rowspan=\"1\"><strong>Clinically inapparent tumour that is not palpable </strong></td></tr><tr><td>T1a</td><td>Tumour incidental histological finding in 5% or less of tissue resected</td></tr><tr><td>T1b</td><td>Tumour incidental histological finding in more than 5% of tissue resected</td></tr><tr><td>T1c</td><td>Tumour identified by needle biopsy (for example, because of elevated PSA)</td></tr><tr><td rowspan=\"1\"><strong>T2 </strong></td><td rowspan=\"1\"><strong>Tumour that is palpable and confined within the prostate</strong></td></tr><tr><td>T2a</td><td>Tumour involves half of one lobe or less</td></tr><tr><td>T2b</td><td>Tumour involves more than half of one lobe, but not both lobes</td></tr><tr><td>T2c</td><td>Tumour involves both lobes</td></tr><tr><td rowspan=\"1\"><strong>T3</strong></td><td rowspan=\"1\"><strong>Tumour extends through the prostatic capsule</strong></td></tr><tr><td>T3a</td><td>Extracapsular extension (unilateral or bilateral)</td></tr><tr><td>T3b</td><td>Tumour invades seminal vesicle(s)</td></tr><tr><td rowspan=\"1\"><strong>T4</strong></td><td rowspan=\"1\"><strong>Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles, and/or pelvic wall</strong></td></tr><tr><td colspan=\"2\" rowspan=\"1\"><strong>N — Regional lymph nodes</strong> †</td></tr><tr><td>NX</td><td>Regional lymph nodes cannot be assessed</td></tr><tr><td>N0</td><td>No regional lymph node metastasis</td></tr><tr><td>N1</td><td>Regional lymph node metastasis</td></tr><tr><td colspan=\"2\" rowspan=\"1\"><strong>M – Distant metastasis </strong>‡</td></tr><tr><td>M0</td><td>No distant metastasis</td></tr><tr><td>M1a</td><td>Non-regional lymph node(s)</td></tr><tr><td>M1b</td><td>Bone(s)</td></tr><tr><td>M1c</td><td>Other site(s) </td></tr><tr><td colspan=\"2\"> * Invasion into the prostatic apex, or into (but not beyond) the prostate capsule, is classified as T2, not T3. † Metastasis no larger than 0.2 cm can be designated pNmi. ‡ When more than one site of metastasis is present, the most advanced category should be used.</td></tr><tr><td colspan=\"2\"><strong>Source:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">EAU, 2017</a>]</td></tr></tbody></table><!-- end field c686103d-4875-4839-818e-a7bb00e9b4d7 --><!-- end item 498dfa03-c2bb-4bf5-9168-a7bb00e9ac31 -->","subChapters":[]},{"id":"7a14ed3b-e08a-5170-aea2-aaf66bec596f","slug":"gleason-score","fullItemName":"Gleason score","depth":4,"htmlHeader":"<!-- begin field f9fa29cd-a7bd-4d38-9246-a7bc00cf0766 --><h4>What is the Gleason score?</h4><!-- end field f9fa29cd-a7bd-4d38-9246-a7bc00cf0766 -->","summary":null,"htmlStringContent":"<!-- begin item 99cb1e7d-66ec-466e-a45f-a7bc00cf04d2 --><!-- begin field 2731c656-f0f2-4a0b-9581-a7bc00cf0766 --><ul><li>When the prostate is biopsied, 10–12 cores will be taken from different parts of the gland.</li><li>The commonest and second most common tumour patterns are analysed and graded from 1 to 5.</li><li>The Gleason score is the sum of these two grades and can range from 2 to 10. </li><li>The tumour grade is classified into either of three risk categories on the basis of the Gleason score:<ul><li>Low: 6 or less. </li><li>Intermediate: 7.</li><li>High: 8–10.</li></ul></li></ul><!-- end field 2731c656-f0f2-4a0b-9581-a7bc00cf0766 --><!-- end item 99cb1e7d-66ec-466e-a45f-a7bc00cf04d2 -->","subChapters":[]},{"id":"b4cb2e92-2f58-5e63-aa50-857ecd3dabd4","slug":"risk-stratification","fullItemName":"Risk stratification","depth":4,"htmlHeader":"<!-- begin field c699214e-9877-4adf-b736-a7bc00d02615 --><h4>Risk stratification for men with localized prostate cancer</h4><!-- end field c699214e-9877-4adf-b736-a7bc00d02615 -->","summary":null,"htmlStringContent":"<!-- begin item 1e75da2d-9af3-4a7c-bbcb-a7bc00d023f9 --><!-- begin field 439ecc36-880a-49ce-947b-a7bc00d02615 --><p><strong>Table 3.</strong> Risk stratification for men with localized prostate cancer according to prostate-specific antigen (PSA) level, Gleason score, and TNM clinical stage.</p><table data-table-id=\"a0863787-1a32-4582-b1dd-acce014c8f6c\"><thead><tr><th colspan=\"1\">Risk of progression</th><th colspan=\"1\">PSA level</th><th colspan=\"1\">—</th><th colspan=\"1\">Gleason score</th><th colspan=\"1\">—</th><th colspan=\"1\">Clinical stage</th></tr></thead><tbody><tr><td colspan=\"1\">Low risk</td><td colspan=\"1\">< 10 nanogram/mL</td><td colspan=\"1\">and</td><td colspan=\"1\">≤6</td><td colspan=\"1\">and</td><td colspan=\"1\">T1–T2a</td></tr><tr><td colspan=\"1\">Intermediate risk</td><td colspan=\"1\">10–20 nanogram/mL</td><td colspan=\"1\">or</td><td colspan=\"1\">7</td><td colspan=\"1\">or</td><td colspan=\"1\">T2b</td></tr><tr><td colspan=\"1\">High risk*</td><td colspan=\"1\">> 20 nanogram/mL</td><td colspan=\"1\">or</td><td colspan=\"1\">8–10</td><td colspan=\"1\">or</td><td colspan=\"1\">≥T2c</td></tr><tr><td colspan=\"6\">* This also includes locally advanced prostate cancer</td></tr><tr><td colspan=\"6\"><strong>Source: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>]</td></tr></tbody></table><!-- end field 439ecc36-880a-49ce-947b-a7bc00d02615 --><!-- end item 1e75da2d-9af3-4a7c-bbcb-a7bc00d023f9 -->","subChapters":[]},{"id":"d150d883-787d-51b4-a18a-21edaed15e5d","slug":"treatment-options-for-localized-prostate-cancer","fullItemName":"Treatment options for localized prostate cancer","depth":4,"htmlHeader":"<!-- begin field efb027bd-5707-4371-926f-7b208ffbcc98 --><h4>What are the treatment options for localized prostate cancer?</h4><!-- end field efb027bd-5707-4371-926f-7b208ffbcc98 -->","summary":null,"htmlStringContent":"<!-- begin item 194f4cff-ccff-4741-b693-b9d7a789f375 --><!-- begin field 3cd9c6f4-3d71-4e96-869e-a7c100cd3e69 --><ul><li><strong>For men with: </strong><ul><li><strong>Low risk </strong>—<strong> </strong>active surveillance can be offered. Other treatments that can be considered include:<ul><li>Watchful waiting, radical prostatectomy, or radical radiotherapy (external-beam radiotherapy [EBR], or brachytherapy).</li></ul></li><li><strong>Intermediate risk </strong>—<strong> </strong>radical prostatectomy, or radical radiotherapy with 6 months of androgen deprivation therapy (before, during or after radiotherapy) can be offered (rather than radical radiotherapy or androgen therapy alone).<ul><li>Other treatments that can be considered include watchful waiting, active surveillance, or high-dose rate brachytherapy in combination with EBR.</li></ul></li><li><strong>High risk </strong>—<strong> </strong>radical prostatectomy, or radical radiotherapy with 6 months of androgen deprivation therapy (before, during or after radiotherapy) can be offered (rather than radical radiotherapy or androgen therapy alone) if there is a realistic prospect of long-term disease control. Androgen deprivation therapy may be continued for up to 3 years.<ul><li>Other treatments that can be considered include watchful waiting or high-dose rate brachytherapy in combination with EBR.</li><li>Active surveillance is not appropriate.</li></ul></li><li>High-intensity focused ultrasonography (HIFU) and cryotherapy should not be considered except as part of a clinical trial comparing use with established interventions.</li></ul></li></ul><!-- end field 3cd9c6f4-3d71-4e96-869e-a7c100cd3e69 --><!-- end item 194f4cff-ccff-4741-b693-b9d7a789f375 -->","subChapters":[]},{"id":"2cb3d4cc-103a-54f7-9197-ef9a92cf5c4f","slug":"basis-for-recommendation-1d7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6e73bc9d-25ac-4399-91f1-f60014fcb3ea --><h4>Basis for recommendation</h4><!-- end field 6e73bc9d-25ac-4399-91f1-f60014fcb3ea -->","summary":null,"htmlStringContent":"<!-- begin item 1d7fdd67-4262-4574-b8f9-f2e15eb484ee --><!-- begin field 34172b58-ba08-4b2f-8f99-cac68979499b --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and managemen</em>t [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>] and the European Association of Urology (EAU) guideline <em>Prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">EAU, 2017</a>].</p><!-- end field 34172b58-ba08-4b2f-8f99-cac68979499b --><!-- end item 1d7fdd67-4262-4574-b8f9-f2e15eb484ee -->","subChapters":[]}]},{"id":"46a00988-6e76-573f-838d-d407053c2080","slug":"watchful-waiting-active-surveillance","fullItemName":"Watchful waiting/active surveillance","depth":3,"htmlHeader":"<!-- begin field 74f5bc6b-fb5b-47d5-aaa2-7c1549f9c2be --><h3>Watchful waiting/active surveillance</h3><!-- end field 74f5bc6b-fb5b-47d5-aaa2-7c1549f9c2be -->","summary":null,"htmlStringContent":"<!-- begin item 9db4a9a8-123c-4dc1-b99f-43e28ebe096a --><!-- end item 9db4a9a8-123c-4dc1-b99f-43e28ebe096a -->","subChapters":[{"id":"727dbade-4432-5589-a958-69c54d0f25aa","slug":"watchful-waiting","fullItemName":"Watchful waiting","depth":4,"htmlHeader":"<!-- begin field 19eacc2a-ff72-405e-8e63-7de2b838a880 --><h4>What is watchful waiting, and when is it an appropriate treatment option for prostate cancer?</h4><!-- end field 19eacc2a-ff72-405e-8e63-7de2b838a880 -->","summary":null,"htmlStringContent":"<!-- begin item 7b12f26c-44b0-4448-82e8-77a78381606e --><!-- begin field c7352d68-3d53-4a41-bf89-0eb3858dab4e --><ul><li>During watchful waiting the man is followed up regularly in primary care — he will be monitored for disease progression in order to avoid treatment unless symptoms appear.<ul><li>This includes regular clinical assessments and repeat prostate-specific antigen (PSA) testing, but not repeated digital rectal examination or prostate biopsies. </li></ul></li><li>Watchful waiting is often suitable for older men, or men with significant comorbidities, or slowly progressing tumours who are likely to die of other causes and not suffer significant morbidity from their prostate cancer. It is an option for men in any prognostic risk group.</li><li>If symptoms develop (for example bone pain), or PSA levels rise rapidly, the man should be reviewed by the urological cancer service to consider starting palliative treatment. </li></ul><!-- end field c7352d68-3d53-4a41-bf89-0eb3858dab4e --><!-- end item 7b12f26c-44b0-4448-82e8-77a78381606e -->","subChapters":[{"id":"61e18808-fa9d-5f57-9fad-01d063c369a4","slug":"basis-for-recommendation-580","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 7eb8f21a-0835-491a-8805-fa09293b5600 --><h5>Basis for recommendation</h5><!-- end field 7eb8f21a-0835-491a-8805-fa09293b5600 -->","summary":null,"htmlStringContent":"<!-- begin item 5800fceb-9f20-4b81-b6c4-3e0938560fea --><!-- begin field 2c977177-e847-499d-a199-35038ce79003 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>] and the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</p><!-- end field 2c977177-e847-499d-a199-35038ce79003 --><!-- end item 5800fceb-9f20-4b81-b6c4-3e0938560fea -->","subChapters":[]}]},{"id":"f9078ea0-9112-5ab2-9e7c-f3b9e0ec4d1a","slug":"active-surveillance","fullItemName":"Active surveillance","depth":4,"htmlHeader":"<!-- begin field 527d19ae-2bf6-4d95-b596-64c33e8cd3d2 --><h4>What is active surveillance, and when is it an appropriate treatment option for prostate cancer?</h4><!-- end field 527d19ae-2bf6-4d95-b596-64c33e8cd3d2 -->","summary":null,"htmlStringContent":"<!-- begin item c297d5f5-91ff-4ed0-b858-2f6eb3fe2a44 --><!-- begin field 89d6e300-d39f-43c8-be89-a7c100e93fd0 --><ul><li>Active surveillance involves frequent serial prostate-specific antigen (PSA) tests, digital rectal examinations, and prostate biopsies. <strong>See Table 4 for a surveillance protocol</strong>.<ul><li>The difference from <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/#watchful-waiting\">watchful waiting</a> is that repeating the prostate biopsy at intervals depending on age and PSA levels allows the man's prognostic risk category to reassessed. The aim of active surveillance is to safely reduce the risk of over treatment, as treatment is offered only when the risk increases.</li></ul></li><li>If there is evidence of disease progression, the man should be offered <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/\">radical treatment</a>. His decision should be informed by his preferences, comorbidities, and life expectancy.</li><li>Active surveillance is the preferred option for men with low prognostic risk who are suitable for <a class=\"topic-reference internal-reference\" href=\"/topics/prostate-cancer/management/management/\">radical treatment</a> in the event of disease progression. It is an option for men at intermediate risk who do not wish to have immediate radical prostatectomy or radical radiotherapy. It is not recommended for men at high risk.</li></ul><p><strong>Table 4. </strong>Protocol for active surveillance of prostate cancer.</p><table data-table-id=\"741f8865-dc64-4747-9b2c-acce014c8fd9\"><thead><tr><th scope=\"col\">Timing</th><th scope=\"col\">Tests*</th></tr></thead><tbody><tr><td>At enrolment</td><td><ul><li>Multiparametric MRI (mpMRI) if not previously performed</li></ul></td></tr><tr><td>Year 1</td><td><ul><li>Every 3–4 months: measure prostate-specific antigen (PSA)<sup>†</sup></li><li>Throughout active surveillance: monitor PSA kinetics<sup>‡</sup></li><li>Every 6–12 months: digital rectal examination (DRE)<sup>§</sup></li><li>At 12 months: prostate rebiopsy</li></ul></td></tr><tr><td>Years 2–4</td><td><ul><li>Every 3–6 months: measure PSA<sup>†</sup></li><li>Throughout active surveillance: monitor PSA kinetics<sup>‡</sup></li><li>Every 6–12 months: DRE<sup>§</sup></li></ul></td></tr><tr><td>Year 5 (and every year thereafter)</td><td><ul><li>Every 6 months: measure PSA<sup>†</sup></li><li>Throughout active surveillance: monitor PSA kinetics<sup>‡</sup></li><li>Every 12 months: DRE<sup>§</sup></li></ul></td></tr><tr><td colspan=\"2\">*If there is concern about clinical or PSA changes at any time during active surveillance, reassess with mpMRI and/or rebiopsy. †May be carried out in primary care if there are agreed shared-care protocols and recall systems. ‡May include PSA doubling time and velocity. §Should be performed by a healthcare professional with expertise and confidence in performing DRE.</td></tr><tr><td colspan=\"2\"><strong>Source:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>]</td></tr></tbody></table><!-- end field 89d6e300-d39f-43c8-be89-a7c100e93fd0 --><!-- end item c297d5f5-91ff-4ed0-b858-2f6eb3fe2a44 -->","subChapters":[{"id":"3f0dc7c2-0468-596f-9f57-90fb0d3ae105","slug":"basis-for-recommendation-a2f","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 24be9efe-54ca-45c7-ad44-0a204a88b171 --><h5>Basis for recommendation</h5><!-- end field 24be9efe-54ca-45c7-ad44-0a204a88b171 -->","summary":null,"htmlStringContent":"<!-- begin item a2f8e45b-75ac-4ed6-9330-8b4f89088bfe --><!-- begin field 84e3b1c2-4728-4ddf-b612-f236fe3c8086 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field 84e3b1c2-4728-4ddf-b612-f236fe3c8086 --><!-- end item a2f8e45b-75ac-4ed6-9330-8b4f89088bfe -->","subChapters":[]}]}]},{"id":"dfb71c50-3f27-5b83-a97e-5af3cac3f6c7","slug":"radical-treatments","fullItemName":"Radical treatments","depth":3,"htmlHeader":"<!-- begin field 71a5fbed-f6f0-4ae9-bc85-25c22497f932 --><h3>Radical treatments</h3><!-- end field 71a5fbed-f6f0-4ae9-bc85-25c22497f932 -->","summary":null,"htmlStringContent":"<!-- begin item 04ddb582-ca60-4e42-87c7-4187816a4209 --><!-- end item 04ddb582-ca60-4e42-87c7-4187816a4209 -->","subChapters":[{"id":"c1744421-4d88-5ebd-8f65-c205c619dbc4","slug":"radical-prostatectomy","fullItemName":"Radical prostatectomy","depth":4,"htmlHeader":"<!-- begin field 0b5a5b91-ccd6-4f27-8d04-d978e589a607 --><h4>What is radical prostatectomy, and when is it appropriate treatment for prostate cancer?</h4><!-- end field 0b5a5b91-ccd6-4f27-8d04-d978e589a607 -->","summary":null,"htmlStringContent":"<!-- begin item 3a0f3b7b-81c1-4ae8-8308-889359363d2c --><!-- begin field d3682b73-c751-4fd4-881d-aed206e0394c --><ul><li>The aim of radical prostatectomy is to remove the entire prostate gland and eradicate the disease. It can be performed by open, laparoscopic, or robot-assisted surgery.</li><li><strong>Risks associated with radical prostatectomy </strong>include urinary incontinence, erectile dysfunction, and incomplete resection of the tumour.<ul><li>Complete tumour removal is not always achieved, and approximately 20% of men develop biochemical or clinical recurrence of prostate cancer.</li></ul></li><li><strong>Radical prostatectomy is an appropriate treatment option for:</strong><ul><li><strong>Localized prostate cancer </strong>—<strong> </strong>it can be considered in men at low prognostic risk, and is a preferred option for men at intermediate risk and those at high risk who have a realistic chance of gaining long-term control of the disease.<ul><li>It is not common to offer it to men older than 70 years of age.</li></ul></li><li><strong>Biochemical relapse after radical radiotherapy </strong>—<strong> </strong>an option for men who have biochemical relapse with increasing prostate-specific antigen (PSA) levels after radical radiotherapy. However, the risk of incontinence, impotence, and rectal damage is higher than when it is used as primary treatment.</li><li><strong>Locally advanced prostate cancer </strong>— surgery alone does not normally eradicate this, and the rate of progression of the disease varies considerably. Men normally receive radiotherapy or hormone therapy.<ul><li>Men with locally advanced prostate cancer should not be offered immediate post-operative radiotherapy or adjuvant hormonal therapy except as part of a clinical trial.</li></ul></li></ul></li></ul><!-- end field d3682b73-c751-4fd4-881d-aed206e0394c --><!-- end item 3a0f3b7b-81c1-4ae8-8308-889359363d2c -->","subChapters":[{"id":"23f9f0b9-1c86-5d0a-b8af-1162e269cc77","slug":"basis-for-recommendation-eb5","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 94f92c4f-10dc-4498-a7d7-b341a48d786e --><h5>Basis for recommendation</h5><!-- end field 94f92c4f-10dc-4498-a7d7-b341a48d786e -->","summary":null,"htmlStringContent":"<!-- begin item eb533c98-e818-4e3f-89c0-e35462874cce --><!-- begin field fad2959f-a8c9-44c5-bb09-220d79ec6951 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>] and the European Association of Urology (EAU) guideline <em>Prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">EAU, 2017</a>].</p><!-- end field fad2959f-a8c9-44c5-bb09-220d79ec6951 --><!-- end item eb533c98-e818-4e3f-89c0-e35462874cce -->","subChapters":[]}]},{"id":"60099e91-86ee-5015-9465-1905930b9bef","slug":"external-beam-radiotherapy","fullItemName":"External-beam radiotherapy","depth":4,"htmlHeader":"<!-- begin field c1ea6864-3d23-4fc0-80ab-011baab40178 --><h4>What is external-beam radiotherapy, and when is it an appropriate treatment for prostate cancer?</h4><!-- end field c1ea6864-3d23-4fc0-80ab-011baab40178 -->","summary":null,"htmlStringContent":"<!-- begin item 4e66f247-8aba-4a53-b122-048390c400cf --><!-- begin field 19cc90c8-8f68-4858-840f-2081677d94ff --><ul><li>External-beam radiotherapy (EBRT) directs an external source of radiation at the tumour from outside the body.<ul><li>Intensity modulated radiotherapy (IMRT) is the accepted best standard for EBRT.</li></ul></li><li><strong>Adverse effects</strong> of EBRT short-term include bowel and bladder problems. Long-term complications include erectile dysfunction and urinary problems. <ul><li>There is a small increased risk of colorectal cancer after EBRT.</li></ul></li><li><strong>EBRT is an appropriate treatment option for:</strong><ul><li><strong>Localized prostate cancer </strong>—<strong> </strong>it can be considered for men at low prognostic risk, and is a preferred option for men at intermediate risk and those at high risk (who have a realistic chance of gaining long-term control of the disease) in combination with 6 months of androgen deprivation therapy (before, during or after EBRT), rather than either therapy alone.<ul><li>For men with high risk localised prostate cancer, androgen deprivation therapy may be continued for up to 3 years.  </li><li>EBRT may be combined with high-dose rate (HDR) brachytherapy for men with intermediate or high risk. </li></ul></li><li><strong>Biochemical relapse after radical prostatectomy </strong>— radiotherapy to the prostate bed is recommended for men who experience biochemical relapse with increasing prostate-specific antigen (PSA) levels after radical prostatectomy, provided that they do not have metastases.</li><li><strong>Locally advanced disease </strong>— EBRT may be used in combination with HDR brachytherapy.</li></ul></li></ul><!-- end field 19cc90c8-8f68-4858-840f-2081677d94ff --><!-- end item 4e66f247-8aba-4a53-b122-048390c400cf -->","subChapters":[{"id":"9f2700d4-7d17-5371-8cc1-408b9308dd14","slug":"basis-for-recommendation-7b3","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 8c10af8d-0a7b-4b5c-8b9a-6edcd4824f04 --><h5>Basis for recommendation</h5><!-- end field 8c10af8d-0a7b-4b5c-8b9a-6edcd4824f04 -->","summary":null,"htmlStringContent":"<!-- begin item 7b3a98a8-6cad-4de0-ac26-c5fc6d64a8c6 --><!-- begin field 07bffe1d-96f8-49bb-b492-1264b27f8e30 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>] the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>] and the European Association of Urology (EAU) guideline <em>Prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">EAU, 2017</a>].</p><!-- end field 07bffe1d-96f8-49bb-b492-1264b27f8e30 --><!-- end item 7b3a98a8-6cad-4de0-ac26-c5fc6d64a8c6 -->","subChapters":[]}]},{"id":"e091e95f-5763-5fd2-8344-e5b9d08c3728","slug":"brachytherapy","fullItemName":"Brachytherapy","depth":4,"htmlHeader":"<!-- begin field 1a2a261e-a0da-4eee-a2a4-7eb4eabb925d --><h4>What is brachytherapy, and when is it appropriate treatment for men with prostate cancer?</h4><!-- end field 1a2a261e-a0da-4eee-a2a4-7eb4eabb925d -->","summary":null,"htmlStringContent":"<!-- begin item 1166bc30-e8c7-40c2-8b8c-8bb18886efe0 --><!-- begin field 5d385080-3708-42ad-9e94-db39273ce940 --><ul><li>Brachytherapy is a type of radiotherapy in which the radioactive source is implanted in the prostate.<ul><li>Low-dose rate (LDR) brachytherapy involves permanent implantation with radioactive seeds. </li><li>High-dose rate (HDR) brachytherapy involves insertion of fine catheters, through which a radioactive source is temporarily passed. <ul><li>The overall dose for HDR is less than LDR, so it is given in conjunction with external beam radiotherapy (EBRT). </li></ul></li></ul></li><li><strong>Adverse effects </strong>include alteration of urinary and bowel function, and erectile dysfunction.</li><li><strong>Brachytherapy is an appropriate treatment option for:</strong><ul><li><strong>Localized prostate cancer </strong>— for men at low prognostic risk and for men at intermediate or high risk, HDR brachytherapy in combination with EBRT.</li><li><strong>Locally advanced prostate cancer </strong>— HDR brachytherapy in combination with EBRT.</li></ul></li><li>Brachytherapy should not be used alone for men with high-risk localised prostate cancer.</li></ul><!-- end field 5d385080-3708-42ad-9e94-db39273ce940 --><!-- end item 1166bc30-e8c7-40c2-8b8c-8bb18886efe0 -->","subChapters":[{"id":"81a79976-3819-51b7-8d58-9913f23ae08a","slug":"basis-for-recommendation-8ce","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field b80dc053-b23a-4604-83ab-d055f7195396 --><h5>Basis for recommendation</h5><!-- end field b80dc053-b23a-4604-83ab-d055f7195396 -->","summary":null,"htmlStringContent":"<!-- begin item 8cef186c-abf1-4af9-8bd3-c2b99c7a9cab --><!-- begin field dab9b197-6dc4-49db-9401-2f79fe4ed516 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2015a</a>], <em>High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2006</a>], and the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</p><!-- end field dab9b197-6dc4-49db-9401-2f79fe4ed516 --><!-- end item 8cef186c-abf1-4af9-8bd3-c2b99c7a9cab -->","subChapters":[]}]},{"id":"1cb17af4-2d18-5956-a3ed-1bda76d484dd","slug":"high-intensity-focused-ultrasound","fullItemName":"High-intensity focused ultrasound","depth":4,"htmlHeader":"<!-- begin field fcaa9f3a-6a0d-4842-8d7a-08658fd0357d --><h4>What is high-intensity focused ultrasound (HIFU), and when is it used to treat prostate cancer?</h4><!-- end field fcaa9f3a-6a0d-4842-8d7a-08658fd0357d -->","summary":null,"htmlStringContent":"<!-- begin item ff36bc75-16d0-484e-9a9c-738c725213ce --><!-- begin field 2244ac43-f8f2-42aa-8b7d-25a6f28d50d7 --><ul><li>High-intensity focused ultrasound (HIFU) uses ultrasound waves to heat the prostate gland and destroy the tissue.</li><li><strong>Adverse effects</strong> of HIFU include erectile dysfunction, urinary incontinence, and rectal damage. </li><li>HIFU is not recommended except as part of a clinical trial in which it is compared with established interventions.</li><li>HIFU may be an appropriate treatment option for:<ul><li><strong>Localized cancer of the prostate.</strong></li><li><strong>Biochemical relapse after radiotherapy for prostate cancer. </strong></li><li><strong>Locally advanced disease</strong>.</li></ul></li></ul><!-- end field 2244ac43-f8f2-42aa-8b7d-25a6f28d50d7 --><!-- end item ff36bc75-16d0-484e-9a9c-738c725213ce -->","subChapters":[{"id":"82663e21-1cfa-5d9a-b3d5-26a70c71ae3f","slug":"basis-for-recommendation-ad3","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field a4ad0940-b59c-41b8-bd11-ec701230eba8 --><h5>Basis for recommendation</h5><!-- end field a4ad0940-b59c-41b8-bd11-ec701230eba8 -->","summary":null,"htmlStringContent":"<!-- begin item ad31f18c-d506-42d4-b4e5-c2874d4eecab --><!-- begin field e34ba220-4c5c-4c46-babe-76cb5165ae71 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Prostate cancer: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>]<em> </em>and <em>High-intensity focused ultrasound for prostate cancer </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2005a</a>] and the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</p><!-- end field e34ba220-4c5c-4c46-babe-76cb5165ae71 --><!-- end item ad31f18c-d506-42d4-b4e5-c2874d4eecab -->","subChapters":[]}]},{"id":"5b87544a-a6e6-5e93-a98f-44e331a15498","slug":"cryotherapy","fullItemName":"Cryotherapy","depth":4,"htmlHeader":"<!-- begin field f4edf34d-26c0-4974-b010-e26bce653864 --><h4>What is cryotherapy, and when is it used to treat prostate cancer?</h4><!-- end field f4edf34d-26c0-4974-b010-e26bce653864 -->","summary":null,"htmlStringContent":"<!-- begin item 2c807c03-6e05-47d2-aedc-3d971ad28ef1 --><!-- begin field ce7254a3-0db9-4bf9-9e19-def4e5943e67 --><ul><li>Cryotherapy is used to destroy the prostate tissue by freezing.</li><li><strong>Adverse effects</strong> of cryotherapy include erectile dysfunction, urinary incontinence, and rectal damage.</li><li>Cryotherapy is not recommended except as part of a clinical trial in which it is compared with established interventions.</li><li>Cryotherapy may be an appropriate treatment option for:<ul><li><strong>Localized cancer of the prostate.</strong></li><li><strong>Biochemical relapse after radical radiotherapy for prostate cancer.</strong></li><li><strong>Locally advanced prostate cancer.</strong></li></ul></li></ul><!-- end field ce7254a3-0db9-4bf9-9e19-def4e5943e67 --><!-- end item 2c807c03-6e05-47d2-aedc-3d971ad28ef1 -->","subChapters":[{"id":"d511240a-f314-5aa7-8739-2a5ff487011e","slug":"basis-for-recommendation-8fa","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field b18722e8-af09-446e-b256-f347ac0de044 --><h5>Basis for recommendation</h5><!-- end field b18722e8-af09-446e-b256-f347ac0de044 -->","summary":null,"htmlStringContent":"<!-- begin item 8fac453f-ae1d-4bcd-bb01-d68574fcbb08 --><!-- begin field b1adea7e-4e5b-43c5-afa1-a0aaf70ac87f --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], <em>Cryotherapy for recurrent prostate cancer </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2005b</a>], <em>Cryotherapy as a primary treatment for prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2005c</a>], and the Public Health England (PHE) guidance <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">PHE, 2016</a>].</p><!-- end field b1adea7e-4e5b-43c5-afa1-a0aaf70ac87f --><!-- end item 8fac453f-ae1d-4bcd-bb01-d68574fcbb08 -->","subChapters":[]}]}]},{"id":"4fc706a9-e36a-5e79-9bba-f26f36e1b1ca","slug":"adjunctive-palliative-treatments","fullItemName":"Adjunctive and palliative treatments","depth":3,"htmlHeader":"<!-- begin field f76d6baf-58fe-4982-98a2-278e29b60154 --><h3>Adjunctive and palliative treatments</h3><!-- end field f76d6baf-58fe-4982-98a2-278e29b60154 -->","summary":null,"htmlStringContent":"<!-- begin item 81df1bc5-af7a-4359-86ec-81395d2f0fd1 --><!-- end item 81df1bc5-af7a-4359-86ec-81395d2f0fd1 -->","subChapters":[{"id":"02f07f3c-26cb-5122-89d0-21f97bb44718","slug":"hormonal-treatments","fullItemName":"Hormonal treatments","depth":4,"htmlHeader":"<!-- begin field 84832aed-88d8-45e0-81d1-2b605f5114c2 --><h4>What hormonal treatment are used for prostate cancer, and when are they indicated?</h4><!-- end field 84832aed-88d8-45e0-81d1-2b605f5114c2 -->","summary":null,"htmlStringContent":"<!-- begin item 74569b39-4ca4-49f6-adfc-c76ecda5e2af --><!-- begin field d6fb3d7a-03be-4934-aea6-924ffa925117 --><ul><li>Hormonal treatments used for prostate cancer include:<ul><li><strong>Androgen withdrawal </strong>—<strong> </strong>surgery (bilateral orchidectomy) or medical, with luteinizing hormone-releasing hormone (LHRH) agonists (such as goserelin, leuprorelin, triptorelin), or antagonists (such as degarelix). </li><li><strong>Androgen blockade </strong>—<strong> </strong>with drugs that bind to and block the hormone receptors of cancer cells (for example, cyproterone acetate), thus preventing androgens from stimulating cancer growth.</li></ul></li><li>Hormonal treatment may be given at different times.<ul><li><strong>Neoadjuvant therapy </strong>is given for several months before radical treatment with surgery or radiotherapy.</li><li><strong>Concurrent therapy </strong>is given at the same time as radiotherapy.</li><li><strong>Adjuvant therapy </strong>is given after radical treatment with surgery or radiotherapy.</li></ul></li><li>Hormonal treatment may be given continuously, <em>or</em> intermittently. </li><li><strong>The adverse effects of hormonal therapies </strong>include erectile dysfunction, loss of libido, breast swelling, hot flushes, and osteoporosis.</li><li><strong>Hormone therapy is an appropriate treatment option for:</strong><ul><li><strong>Localised prostate cancer </strong>— it can be used before, during or after treatment with radical radiotherapy for men at intermediate, or high risk. </li><li><strong>Biochemical relapse after radical prostatectomy or radiotherapy </strong>— it should not be used routinely unless the man has symptomatic local disease progression, proven metastases, or his prostate-specific antigen (PSA) level has doubled in less than 3 months.</li><li><strong>Locally advanced prostate cancer</strong><ul><li>Neoadjuvant treatment is started 2–3 months before men receive radical radiotherapy for locally advanced prostate cancer. In practice, adjuvant therapy is started at the onset of radiotherapy, and it is recommended that it is continued for 2–3 years (rather than short-term, 6 months). </li><li>Degarelix is an LHRH antagonist, which is licensed for treatment of men with advanced hormone-dependent prostate cancer.</li></ul></li><li><strong>Metastatic prostate cancer </strong><ul><li>Bilateral orchidectomy and continuous LHRH agonist therapy are options, depending on the man's preferences. </li><li>Anti-androgen monotherapy with bicalutamide may be the preferred option for men who hope to retain sexual function and are willing to accept the risk of reduced life expectancy and the possibility of gynaecomastia.</li><li>Abiraterone (an androgen synthesis inhibitor) in combination with prednisone or prednisolone is an option for treating metastatic hormone-relapsed prostate cancer in men who have no, or mild, symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated, and if their disease has progressed on or after one docetaxel-containing chemotherapy regimen.</li><li>Enzalutamide (an androgen receptor antagonist) is an option for treating metastatic hormone-relapsed prostate cancer in people who have no, or mild, symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.</li></ul></li></ul></li></ul><!-- end field d6fb3d7a-03be-4934-aea6-924ffa925117 --><!-- end item 74569b39-4ca4-49f6-adfc-c76ecda5e2af -->","subChapters":[{"id":"ff6c223a-f84c-5476-bd33-b4a0bf1cd35b","slug":"basis-for-recommendation-2a3","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 96aaf306-5221-4e96-b8bf-687b0478d62e --><h5>Basis for recommendation</h5><!-- end field 96aaf306-5221-4e96-b8bf-687b0478d62e -->","summary":null,"htmlStringContent":"<!-- begin item 2a3e4f94-bc2a-422d-a11e-c339b1da1033 --><!-- begin field 04eb0f67-5f9d-4cf2-a895-81154377151d --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], NICE health technology appraisals <em>Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2016b</a>], <em>Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2017</a>], and <em>Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2016c</a>], the European Association of Urology (EAU) guideline <em>Prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">EAU, 2017</a>] and the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>].</p><!-- end field 04eb0f67-5f9d-4cf2-a895-81154377151d --><!-- end item 2a3e4f94-bc2a-422d-a11e-c339b1da1033 -->","subChapters":[]}]},{"id":"15a96847-53d8-5ff0-814a-f7e4c6c2376d","slug":"strontium-89","fullItemName":"Strontium-89","depth":4,"htmlHeader":"<!-- begin field f46c257a-0146-47e9-8a6c-4490fb1b9d7c --><h4>What is strontium-89 therapy, and when is it used for prostate cancer?</h4><!-- end field f46c257a-0146-47e9-8a6c-4490fb1b9d7c -->","summary":null,"htmlStringContent":"<!-- begin item 3a9afa4d-582e-47c3-aca0-ffd56b92ee51 --><!-- begin field 2a8497f8-76e3-4624-9a63-3104c7fc2d2f --><ul><li>The radioactive isotope of strontium, Sr-89, is an option for men with hormone-relapsed prostate cancer and painful bone metastases.</li><li>Strontium-89 is given intravenously and may be used as adjunctive treatment together with other therapies (for example, androgen deprivation therapy).</li></ul><!-- end field 2a8497f8-76e3-4624-9a63-3104c7fc2d2f --><!-- end item 3a9afa4d-582e-47c3-aca0-ffd56b92ee51 -->","subChapters":[{"id":"630adc40-3aa9-5777-9ea3-eb3ea5d0088f","slug":"basis-for-recommendation-923","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 35ec2857-56f9-462a-8895-2e021b87fd5b --><h5>Basis for recommendation</h5><!-- end field 35ec2857-56f9-462a-8895-2e021b87fd5b -->","summary":null,"htmlStringContent":"<!-- begin item 9232cdbb-5fe2-4a1f-895b-2ad843608d78 --><!-- begin field 3e29b4bb-4b4f-43cd-9b60-4bb799e72d20 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field 3e29b4bb-4b4f-43cd-9b60-4bb799e72d20 --><!-- end item 9232cdbb-5fe2-4a1f-895b-2ad843608d78 -->","subChapters":[]}]},{"id":"34bc6d28-2960-57a7-85c5-7ea939971a45","slug":"radium223","fullItemName":"Radium223","depth":4,"htmlHeader":"<!-- begin field c8403038-cdf7-414f-a04b-a7c500c11b3f --><h4>What is Radium–223 therapy, and when is it used for prostate cancer?</h4><!-- end field c8403038-cdf7-414f-a04b-a7c500c11b3f -->","summary":null,"htmlStringContent":"<!-- begin item 1e55e923-2821-4faa-9b84-a7c500c1090c --><!-- begin field d6f4d0d5-b3f3-4d51-8355-a7c500c11b3f --><ul><li>Radium–223 dichloride is a radiopharmaceutical agent designed to deliver alpha radiation to bone metastases without affecting normal bone marrow.</li><li>It is an option for treating hormone-relapsed prostate cancer, and symptomatic bone metastases (with no known visceral metastases) in men who have already had docetaxel, or in whom docetaxel is contraindicated or unsuitable.</li><li>It is administered by intravenous injection every 4 weeks for 6 injections.</li></ul><!-- end field d6f4d0d5-b3f3-4d51-8355-a7c500c11b3f --><!-- end item 1e55e923-2821-4faa-9b84-a7c500c1090c -->","subChapters":[{"id":"ed7de076-d0ec-5b15-91e9-2ed0151187d5","slug":"basis-for-recommendation-746","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 558d9d4e-5ab1-4faf-ab05-a7c500c2da56 --><h5>Basis for recommendation</h5><!-- end field 558d9d4e-5ab1-4faf-ab05-a7c500c2da56 -->","summary":null,"htmlStringContent":"<!-- begin item 746fac8d-24dc-4c2d-9032-a7c500c2d776 --><!-- begin field 006de34e-561e-4b1e-ad36-a7c500c2da56 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2016d</a>].</p><!-- end field 006de34e-561e-4b1e-ad36-a7c500c2da56 --><!-- end item 746fac8d-24dc-4c2d-9032-a7c500c2d776 -->","subChapters":[]}]},{"id":"1bbbd29c-8788-55ee-a3f2-7f0f36446ff7","slug":"chemotherapy","fullItemName":"Chemotherapy","depth":4,"htmlHeader":"<!-- begin field 02d4844c-77dd-4b15-a486-a972deffc751 --><h4>What chemotherapy is used for prostate cancer, and when is it offered?</h4><!-- end field 02d4844c-77dd-4b15-a486-a972deffc751 -->","summary":null,"htmlStringContent":"<!-- begin item 921c1002-e0f9-4c75-a5e5-aef051691898 --><!-- begin field 60939d2f-4527-40d0-a45b-47edc3701f71 --><ul><li>Chemotherapy is an option for men with hormone-relapsed metastatic disease. </li><li><strong>Docetaxel</strong><ul><li>Docetaxel in combination with prednisolone is licensed for hormone-resistant metastatic prostate cancer.</li></ul></li><li><strong>Cabazitaxel</strong><ul><li>Cabazitaxel in combination with prednisone or prednisolone is an option for treating metastatic hormone-relapsed prostate cancer in people whose disease has progressed during or after docetaxel.</li></ul></li><li><strong>Corticosteroids</strong><ul><li>A corticosteroid, such as dexamethasone, is an option as third-line therapy after androgen withdrawal and anti-androgen therapy for men with hormone-refractory prostate cancer.</li></ul></li></ul><!-- end field 60939d2f-4527-40d0-a45b-47edc3701f71 --><!-- end item 921c1002-e0f9-4c75-a5e5-aef051691898 -->","subChapters":[{"id":"6e084743-aeb6-548f-9df3-1b865b4e4011","slug":"basis-for-recommendation-328","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 2485897b-64b2-4b79-a2fd-d615f817ac0e --><h5>Basis for recommendation</h5><!-- end field 2485897b-64b2-4b79-a2fd-d615f817ac0e -->","summary":null,"htmlStringContent":"<!-- begin item 32859967-ec61-43cf-b56a-2b3f871e446e --><!-- begin field 09d23752-a909-47e0-9bc4-dd3feaade7d6 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>], the British Medical Journal (BMJ) best practice guide <em>Prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BMJ, 2017</a>], the American Society of Clinical Oncology (ASCO) guideline <em>Systemic therapy in men with metastatic castration-resistant prostate cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ASCO, 2014</a>] and the NICE technology appraisal <em>Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2016e</a>].</p><!-- end field 09d23752-a909-47e0-9bc4-dd3feaade7d6 --><!-- end item 32859967-ec61-43cf-b56a-2b3f871e446e -->","subChapters":[]}]},{"id":"a8c22232-d7a1-51e6-a040-35b41997e1ab","slug":"bisphosphonates","fullItemName":"Bisphosphonates","depth":4,"htmlHeader":"<!-- begin field 68df8ccf-026d-4ad8-954b-40aca9374c67 --><h4>When are bisphosphonates used in men with prostate cancer?</h4><!-- end field 68df8ccf-026d-4ad8-954b-40aca9374c67 -->","summary":null,"htmlStringContent":"<!-- begin item 9c49e70f-074c-46a4-852c-d59ef0e83885 --><!-- begin field a49c24c8-83a8-4c90-97a1-fd32c8adb5ae --><ul><li>Offer bisphosphonates to men taking androgen deprivation therapy who have osteoporosis. <ul><li>Do not offer bisphosphonates routinely to prevent osteoporosis in men with prostate cancer taking androgen deprivation therapy.</li></ul></li><li>Consider bisphosphonates for pain relief in men with hormone-refractory prostate cancer when other treatments (including analgesics and palliative radiotherapy) have failed.</li><li>Do not offer bisphosphonates to prevent bone metastases or to reduce their complications.</li></ul><!-- end field a49c24c8-83a8-4c90-97a1-fd32c8adb5ae --><!-- end item 9c49e70f-074c-46a4-852c-d59ef0e83885 -->","subChapters":[{"id":"16141524-bb44-5798-b59d-675d3ef5914b","slug":"basis-for-recommendation-658","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 2d15b4e6-68b3-458f-a7a0-fbea51fabb46 --><h5>Basis for recommendation</h5><!-- end field 2d15b4e6-68b3-458f-a7a0-fbea51fabb46 -->","summary":null,"htmlStringContent":"<!-- begin item 658a8582-6b6f-4a86-97b3-bf98955e49d4 --><!-- begin field 5167af88-51d9-44f0-bf2a-95b1067c7db5 --><p>This information is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><!-- end field 5167af88-51d9-44f0-bf2a-95b1067c7db5 --><!-- end item 658a8582-6b6f-4a86-97b3-bf98955e49d4 -->","subChapters":[]}]}]},{"id":"a4e9f1dd-c65f-58f3-b11e-4e71e29d9b65","slug":"information-support-for-patients","fullItemName":"Information and support for patients","depth":3,"htmlHeader":"<!-- begin field 0f0aefe4-f87b-4847-aa7d-586705416d3e --><h3>What information and support should I give men with prostate cancer? </h3><!-- end field 0f0aefe4-f87b-4847-aa7d-586705416d3e -->","summary":null,"htmlStringContent":"<!-- begin item 4ee802bd-a70f-4b9b-8e99-8ed02ae0e28c --><!-- begin field ef382cb2-15fa-4ce0-ad57-a7bb00c5436a --><ul><li>Discuss all relevant management options with men, and if they wish, their partners or carers, irrespective of whether they are available through local services. This should include:<ul><li>The risks and benefits of treatment, and that there is limited evidence for some treatment options.</li><li>The short- and long-term adverse effects of treatment and when and how to report them. </li><li>The follow up required, including the purpose, duration, frequency, and location (hospital or primary care).</li></ul></li><li>Offer men with prostate cancer advice on how to access information and support from websites, local and national cancer information services, and from cancer support groups, including: <ul><li><strong>Cancer Research UK</strong> — the section on living with prostate cancer includes information on:<ul><li><a data-hyperlink-id=\"219c3da0-1bb4-48ce-9b63-a93100ae8dd2\" href=\"http://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment\">Treatment</a>.</li><li><a data-hyperlink-id=\"23ad4581-7b25-47f5-9d6a-a93100ae8e0b\" href=\"http://www.cancerresearchuk.org/about-cancer/prostate-cancer/practical-emotional-support/sex-relationships\">Sex and relationships</a>.</li><li><a data-hyperlink-id=\"7962118d-4728-4cf3-b754-a93100ae8e77\" href=\"http://www.cancerresearchuk.org/about-cancer/prostate-cancer/practical-emotional-support/living-with\">Living with prostate cancer</a>.</li><li>Visit <a data-hyperlink-id=\"6b1f0b44-78e5-41a0-8c1f-a93100ae8ee8\" href=\"http://www.cancerresearchuk.org/about-cancer/prostate-cancer\">www.cancerresearchuk.org</a>.</li></ul></li><li><strong>Prostate Cancer UK</strong> — a wide range of publications is available, including:<ul><li><a data-hyperlink-id=\"210dd444-7547-49b8-a061-a93100ae8ef1\" href=\"http://prostatecanceruk.org/media/11617/hifu.pdf\">High intensity focused ultrasound (pdf)</a>.</li><li><a data-hyperlink-id=\"fa3e1301-8413-42c6-88cf-a93100ae8f1f\" href=\"https://prostatecanceruk.org/media/2491116/2627-cryotherapy-factsheet_ver4.pdf\">Cryotherapy (pdf)</a>.</li><li><a data-hyperlink-id=\"68e1f8fb-256d-4873-9b65-a93100ae8f42\" href=\"https://prostatecanceruk.org/prostate-information/our-publications/publications/hormone-therapy\">Hormone therapy (pdf)</a>.</li><li><a data-hyperlink-id=\"0ddec828-de57-4415-8e6d-a93100ae900e\" href=\"http://prostatecanceruk.org/media/11605/1479_permanent_seed_brachytherapy_web.pdf\">Permanent seed brachytherapy (pdf)</a>.</li><li><a data-hyperlink-id=\"9af3c50f-1378-41cc-a3d6-a93100ae9026\" href=\"https://prostatecanceruk.org/prostate-information/our-publications/publications/high-dose-rate-brachytherapy\">High dose rate brachytherapy (pdf)</a>.</li><li><a data-hyperlink-id=\"f0b221cc-ddf7-4b55-b132-a93100ae91ba\" href=\"http://prostatecanceruk.org/media/11602/external_beam_radiotherapy-ifm.pdf\">External beam radiotherapy (pdf)</a>.</li><li><a data-hyperlink-id=\"9a65e05e-7ffe-4f8a-a020-a93100ae91be\" href=\"http://prostatecanceruk.org/media/11611/surgery_radical_prostatectomy-ifm.pdf\">Surgery: radical prostatectomy (pdf)</a>.</li><li><a data-hyperlink-id=\"3e4d9a79-1501-4e05-8da8-a93100ae91d5\" href=\"http://prostatecanceruk.org/media/11599/1196_active_surveillance.pdf\">Active surveillance (pdf)</a>.</li><li><a data-hyperlink-id=\"962c9c77-d5b7-48a8-b4b7-a93100ae91e9\" href=\"http://prostatecanceruk.org/media/41578/newly_diagnosed_booklet.pdf\">Prostate cancer. A guide for newly diagnosed men (pdf)</a>.</li><li><a data-hyperlink-id=\"482cf99c-cfb8-4163-a97c-a93100ae91f6\" href=\"http://prostatecanceruk.org/media/1823882/advanced-prostate-cancer-booklet.pdf\">Advanced prostate cancer. Managing symptoms and getting support (pdf)</a>.</li><li><a data-hyperlink-id=\"72fb7614-d77d-4c50-8366-a93100ae920d\" href=\"http://prostatecanceruk.org/media/11857/urinary_problems.pdf\">Urinary problems after prostate cancer treatment (pdf)</a>.</li><li><a data-hyperlink-id=\"47651f9b-0832-451c-a910-a93100ae9219\" href=\"http://prostatecanceruk.org/media/1689186/prostate-cancer-and-your-sex-life-booklet.pdf\">Prostate cancer and your sex life (pdf)</a>.</li><li><a data-hyperlink-id=\"91d796f3-f1e7-4398-b5a3-a93100ae9315\" href=\"http://prostatecanceruk.org/media/11576/diet_physical_activity_and_prostate_cancer_final.pdf\">Diet, activity and your risk of prostate cancer (pdf)</a>.</li><li><a data-hyperlink-id=\"a5991614-f4b9-4d3a-a1c9-a93100ae932d\" href=\"https://prostatecanceruk.org/prostate-information/our-publications/publications/if-your-prostate-cancer-comes-back-a-guide-to-treatment-and-support\">If your prostate cancer comes back: a guide to treatment and support (pdf)</a>.</li><li><a data-hyperlink-id=\"6dcee200-eeac-4cee-b431-a93100ae9432\" href=\"http://prostatecanceruk.org/media/41582/1280_living_with_hormone_therapy.pdf\">Living with hormone therapy. A guide for men with prostate cancer (pdf)</a>.</li><li>Visit <a data-hyperlink-id=\"968253b7-adb1-4a6b-87a7-a93100ae944a\" href=\"http://prostatecanceruk.org/\">www.prostatecanceruk.org</a>.</li></ul></li><li><strong>Macmillan Cancer Support</strong> — the section on living with prostate cancer includes information on:<ul><li><a data-hyperlink-id=\"b88d1112-bd4b-44b4-a076-a93100ae9526\" href=\"http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Livingwithprostatecancer/Livingwithandaftercancer.aspx\">Coping with prostate cancer</a>.</li><li><a data-hyperlink-id=\"84486e2c-4459-4799-adf0-a93100ae957a\" href=\"http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Livingwithprostatecancer/Sideeffects.aspx\">Side effects and symptoms</a>.</li><li><a data-hyperlink-id=\"5ee87127-4a5b-4b98-b6e9-a93100ae95a9\" href=\"http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Livingwithprostatecancer/Followup.aspx\">Follow up</a>.</li><li>Visit <a data-hyperlink-id=\"0493cbd1-5c92-4ab8-9f59-a93100ae960c\" href=\"http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Prostate/Prostatecancer.aspx\">www.macmillan.org.uk</a>.</li></ul></li><li><strong>NHS A-Z</strong> — a comprehensive health information service, which includes information on prostate cancer.<ul><li>Visit <a data-hyperlink-id=\"48e23564-9ffa-4029-811a-a93100ae9648\" href=\"https://www.nhs.uk/conditions/\">www.nhs.uk</a>.</li></ul></li><li><strong>Prostate Link UK </strong>— provides links to quality-assessed sources of information about the questions men with prostate cancer commonly want to ask.<ul><li>Visit <a data-hyperlink-id=\"68b8199e-5b07-458d-ba59-a93100ae968a\" href=\"http://www.prostate-link.org.uk/\">www.prostate-link.org.uk</a>.</li></ul></li><li><strong>Healthtalkonline </strong>— allows people to read other people's experiences of health and illness. The information is based on research led by experts at the University of Oxford.<ul><li>Visit <a data-hyperlink-id=\"eda501c5-4c86-4524-944d-a93100ae9d43\" href=\"http://www.healthtalkonline.org/Cancer/Prostate_Cancer\">www.healthtalkonline.org</a>.</li></ul></li></ul></li></ul><!-- end field ef382cb2-15fa-4ce0-ad57-a7bb00c5436a --><!-- end item 4ee802bd-a70f-4b9b-8e99-8ed02ae0e28c -->","subChapters":[{"id":"78412a1e-7d07-5805-bbd5-c7eb1bc32d53","slug":"basis-for-recommendation-7ea","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a832e1ca-b06f-4c3b-9d87-a7c200ea6efa --><h4>Basis for recommendation</h4><!-- end field a832e1ca-b06f-4c3b-9d87-a7c200ea6efa -->","summary":null,"htmlStringContent":"<!-- begin item 7eafe3cb-b643-401a-bc68-a7c200ea60ad --><!-- begin field dd466015-953f-403e-afcb-a7c200ea6efa --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Prostate cancer: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>].</p><ul><li>The resources listed have been identified by CKS.</li></ul><!-- end field dd466015-953f-403e-afcb-a7c200ea6efa --><!-- end item 7eafe3cb-b643-401a-bc68-a7c200ea60ad -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}